Greater investment in AI and data security are among the keys.
The COVID-19 pandemic brought on an era in which nearly every activity of our lives went digital. And while many yearn for a return to pre-pandemic days in the healthcare business, the “new normal” is here to stay with even more progression from digital health (the gathering of information) to data-driven healthcare (actionable decisions based on the data). When this happens, organizations will need to demonstrate how this will improve healthcare services in quality, access and efficiency:
The digital transformation of healthcare will be key to achieving these objectives. Below are steps the healthcare industry needs to take to move from simply digital health to data-driven healthcare.
1. Identify and invest. Healthcare organizations need to invest further in AI and other related advanced technologies.Clinical workflows will become more agile by virtue of AI and advanced analytics that automate decision-making processes. The emergence of these technologies requires a transformation from digital health to data-driven healthcare given the fundamental role of data in automated decision making.
2. Improve big data analysis, data quality and availability. Technological devices generate huge amounts of data that can be analyzed to provide real-time clinical or medical care. To extract meaningful value, the data must feature 4 factors to provide important benefits including more accurate staffing; facilitation of chronic care; and a lower rate of medication errors.
3. Embrace technology trends. When done systematically and on a large scale, relatively simple technology solutions will reduce the cost of improving health outcomes. The next generation of innovations including the use of AI and precision medicine, in combining big data analytics and machine learning (ML) algorithms, will enable us to leverage this data better and give rise to new use cases and ways of working.
4. Data security. For an adequate level of data protection, organizations need to follow a blueprint which should include setting up a dedicated corporate figure/committee to (1) monitor and assess regulatory compliance for data processing, (2) define and update data management policies, (3) provide training for those dealing with health data, and (4) implement “secure by design” information systems.
5. Skills development. Insufficient data analytics talent has been a perennial pain point for the healthcare industry. Significant investment in trained teams of data analysts, data managers, and data stewards will be needed to manage the gathering and analysis of data, while developers are needed in software development.
Rebecka Axelsson Wadman
Even with all of these benefits to patient care, healthcare leaders will need to be prepared for some levels of resistance. The key is to communicate effectively with a seriousness of purpose why these advances matter and how their use will directly maintain and improve patient care.
Rebecka Axelsson Wadman is a principal at Arthur D. Little with deep industry expertise in healthcare and life sciences.
Briana Contreras, an editor of Managed Healthcare Executive, spoke with Fred Turner, CEO of Curative, in this month’s episode about the challenges middle-class Americans face in dealing with medical debt, exploring the causes behind it and the impact on overall health.
Listen
Independent Assessment of Syfovre Needed, Argues JAMA Ophthalmologist Viewpoint
December 7th 2023A California retinal specialist argues in a JAMA Ophthalmology viewpoint article that an independent panel of retinal specialists and statisticians should assess the data from clinical trials of Syfovre (pegcetacoplan) because of the lack of a complete FDA scientific analysis of the drug and of peer-reviewed publication.
Read More
Bridging the Diversity Gap in Rare Disease Clinical Trials with Harsha Rajasimha of IndoUSrare
November 8th 2023Briana Contreras, an editor with Managed Healthcare Executive, spoke with Harsha Rajasimha, MD, founder and executive chairman of IndoUSrare, in this month's episode of Tuning in to the C-Suite podcast. The conversation was about how the disparity in diversity and ethnicity in rare disease clinical trials in the U.S. has led to gaps in understanding diseases and conditions, jeopardizing universal health, and increasing the economic burden of healthcare.
Listen